PMID: 18717434Aug 23, 2008Paper

Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed

Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye
Samer E Farah

Abstract

Neovascular age-related macular degeneration presents a therapeutic challenge. The efficacy of pegaptanib sodium, a selective inhibitor of vascular endothelial growth factor 165, was examined as a therapeutic mainstay combined with "as needed" boosts of nonselective vascular endothelial growth factor blockade with bevacizumab or ranibizumab. A retrospective chart review of outcomes of patients treated with pegaptanib and later boosted with bevacizumab or ranibizumab was conducted. Visual acuity, optical coherence tomography, and fluorescein angiography findings were recorded and assessed. During a mean follow-up of 12.1 months, an average of 7.8 injections of pegaptanib 0.3 mg, 1.4 injections of bevacizumab 1.25 mg, and 0.9 injections of ranibizumab 0.5 mg were administered to 17 eyes. In all, 47% of eyes gained 3 or more lines of visual acuity and 76% gained 0 or more lines. Pegaptanib as a mainstay of neovascular age-related macular degeneration therapy with an occasional boost of bevacizumab or ranibizumab appears to be an effective treatment option.

References

Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Oct 6, 2005·Retina·Christine R Gonzales, UNKNOWN VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group
Nov 23, 2005·Oncology·Michael S Gordon, David Cunningham
Feb 7, 2006·Ophthalmology·Robert L AveryMatthew J Giust
Mar 7, 2006·Nature Reviews. Drug Discovery·Eugene W M NgAnthony P Adamis
May 2, 2006·Ophthalmology·UNKNOWN VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupB Katz
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Dec 13, 2006·Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye·Mark S Hughes, Delia N Sang
Jul 31, 2007·Lancet·Tien Y WongPaul Mitchell
Aug 10, 2007·Journal of the National Cancer Institute·Frank A ScappaticciHerbert Hurwitz

❮ Previous
Next ❯

Citations

May 18, 2010·The British Journal of Ophthalmology·Thomas R FribergMauro Goldbaum
May 29, 2010·Seminars in Ophthalmology·Federico RicciFederico Regine
Jan 15, 2014·Survey of Ophthalmology·Anton M Kolomeyer, Marco A Zarbin
Jul 15, 2015·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·Gwyn Samuel WilliamsChristopher Blyth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.